Please assess the completion status of the following clinical trial:

Trial Title: Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression (SAINT-TRD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 22 to 80 years of age.~* Able to provide informed consent.~* Diagnosed with Major Depressive Disorder (MDD) and currently experiencing a Major Depressive Episode (MDE).~* Participants may currently be on a stable and adequate dose of SSRI antidepressant therapy. Participants may choose to not be on antidepressant therapy for the study duration, or to be switched from other classes to a medication from the SSRI class.~* Participants may also have a history of intolerance to at least 2 antidepressant medications. These patients with the intolerance history will not be required to be currently taking an antidepressant medication.~* Participants must qualify as Moderately Treatment Refractory or High Treatment Refractory using the Maudsley staging method.~* Meet the threshold on the total HAMD17 score of \>/=20 at both screening and baseline visits (Day -5/-14 and Day 0).~* Meet the threshold on the total MADRS score of \>/=20 at both screening and baseline visits (Day -5/-14 and Day 0).~* Meet the threshold on the total BDI-II score of \>/=20 at both screening and baseline visits (Day -5/-14 and Day 0).~* In good general health, as ascertained by medical history.~* If female, a status of non-childbearing potential or use of an acceptable form of birth control. The form of birth control will be documented at screening and baseline.~* Concurrent hypnotic therapy (e.g., with zolpidem, zaleplon, melatonin, or trazodone) will be allowed if the therapy has been stable for at least 4 weeks prior to screening and if it is expected to remain stable.~Exclusion Criteria:~* Female of childbearing potential who is not willing to use one of the specified forms of birth control during the study.~* Female that is pregnant or breastfeeding.~* Female with a positive pregnancy test at participation.~* Total HAMD17 score of \< 20 at the screen or baseline visits.~* Total MADRS score of \< 20 at the screen or baseline visits.~* Total BDI-II score of \< 20 at the screen or baseline visits.~* Current diagnosis of a Substance Use Disorder (Abuse or Dependence, as defined by DSM-IV-TR), with the exception of nicotine dependence, at screening or within six months prior to screening.~* Current diagnosis of Axis I disorders other than Dysthymic Disorder, Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Agoraphobia, or Specific Phobia (unless one of these is comorbid and clinically unstable, and/or the focus of the participant's treatment for the past six months or more).~* History of schizophrenia or schizoaffective disorders, or any history of psychotic symptoms in the current or previous depressive episodes.~* Any Axis I or Axis II Disorder, which at screening is clinically predominant to their MDD or has been predominant to their MDD at any time within six months prior to screening.~* Considered at significant risk for suicide during the course of the study.~* Cognitive impairment (as noted by previous diagnoses-including dementia).~* Has a clinically significant abnormality on the screening examination that might affect safety, study participation, or confound interpretation of study results.~* Participation in any clinical trial with an investigational drug or device within the past month or concurrent to study participation.~* Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation.~* History of positive screening urine test for drugs of abuse at screening: cocaine, amphetamines, barbiturates, opiates.~* Current (or chronic) use of opiates.~* History of epilepsy.~* History of rTMS exposure.~* History of any implanted device or psychosurgery for depression.~* Any history of ECT (greater than 8 sessions) without meeting responder criteria~* History of shrapnel or metal in the head or skull.~* Low Treatment Refractory using the Maudsley staging method.~* History of cardiovascular disease or cardiac event.~* History of OCD.~* History of autism spectrum disorder.~* History of intractable migraine~* History of independent sleep disorder.

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Active TBS-DLPFC (Type: EXPERIMENTAL): The active group will receive theta-burst TMS stimulation.
- Sham TBS-DLPFC (Type: SHAM_COMPARATOR): The sham group will receive sham theta-burst TMS stimulation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete